Please assess the completion status of the following clinical trial:

Trial Title: Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* To be eligible to receive continued treatment, subjects must remain eligible to receive study drug at the time of their last Biomed 777-CLP-29 visit~* To continue on survival follow-up, subjects must be in survival follow-up in study Biomed 777-CLP-29~* Written informed consent obtained for subjects who continue study drug treatment~Exclusion Criteria:~* Subjects who have withdrawn consent to participate in Biomed 777-CLP-29 for any reason~* Subjects for whom the investigator considers study participation is no longer in the best interest of those subjects.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).